Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[mTOR and FTY 720 inhibitors].

D Morel1

  • 1Hôpital Pellegrin, Bordeaux.

Presse Medicale (Paris, France : 1983)
|October 2, 2001
PubMed
Summary
This summary is machine-generated.

Sirolimus and everolimus are mTOR inhibitors with manageable side effects, while FTY720 offers a novel mechanism for immunosuppression with a low drug interaction risk. These agents show potential in managing transplant rejection and specific cancers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epigenetic modifiers as new immunomodulatory therapies in solid tumours.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

[Can you do away with anti-nausea drugs in pediatrics?].

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2014
Same author

Pertinence of the Sysmex XE-5000™ parameters: rule of slide review in a context of 'normal' lymphocyte count (defined from control and mantle cell lymphoma blood specimens).

International journal of laboratory hematology·2013
Same author

Preemptive therapy versus valgancyclovir prophylaxis in cytomegalovirus-positive kidney transplant recipients receiving antithymocyte globulin induction.

Transplantation proceedings·2012
Same author

Interobserver concordance in the assessment of features used for the diagnosis of cervical atypical squamous cells and squamous intraepithelial lesions (ASC-US, ASC-H, LSIL and HSIL).

Cytopathology : official journal of the British Society for Clinical Cytology·2011
Same journal

Predictive analytics and risk stratification models in internal medicine: from risk scores to real-time machine learning.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in skin disease therapeutics: from drug discovery to personalized treatment pathways.

Presse medicale (Paris, France : 1983)·2026
Same journal

AI in clinical diagnostics in dermatology: applications, validation, and real-world use cases.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in medical research and publishing: progress, risks, and future perspectives.

Presse medicale (Paris, France : 1983)·2026
Same journal

Ethical, legal, and regulatory challenges in AI-based healthcare tools.

Presse medicale (Paris, France : 1983)·2026
Same journal

Decision-making for clinicians.

Presse medicale (Paris, France : 1983)·2026
See all related articles

Area of Science:

  • Immunology
  • Pharmacology

Background:

  • Sirolimus (rapamycin) is an mTOR inhibitor with dose-dependent side effects, manageable when combined with other immunosuppressants like tacrolimus or cyclosporine.
  • Effective sirolimus plasma concentrations range from 5 to 20 ng/ml, varying with combination therapy.
  • Sirolimus has demonstrated potential in inhibiting metastatic renal adenocarcinoma in mice, with ongoing research into its effects on angiogenesis, fibrosis, and chronic rejection.

Framework:

  • Everolimus (RAD) is an mTOR inhibitor with a short half-life and fewer hematologic effects than sirolimus.
  • Therapeutic dosing of everolimus requires plasma concentrations of at least 3 ng/ml to prevent rejection.
  • Higher everolimus doses (above 15 ng/ml) are associated with an increased risk of thrombocytopenia.

Implementation:

Related Experiment Videos

  • FTY720 represents a new class of immunosuppressant with a unique mechanism of action.
  • FTY720 enhances chemokine receptor expression on T cells, preventing their involvement in rejection.
  • FTY720 possesses a long half-life (108 hours) and minimal risk of drug interactions due to its distinct liver metabolism.

    • Implications:

    • Understanding the pharmacokinetics and pharmacodynamics of sirolimus, everolimus, and FTY720 is crucial for optimizing immunosuppressive therapy.
    • FTY720's novel mechanism and favorable drug interaction profile present a promising alternative in immunosuppression.
    • Further investigation into sirolimus's complex effects on angiogenesis and fibrosis may reveal new therapeutic strategies.